ACHN News 10.78 08/26/2014 04:23:38 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Aug 26, 2014 at 5:23 AM

Achillion Pharmaceuticals (ACHN) 10.78 $ACHN

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - 23 mins ago
The trading panel looked at banks and the top buy and sell candidates for right now.

Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.

Nasdaq stocks posting largest percentage increases
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Most active Nasdaq-traded stocks
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

More Biotech Mergers: Roche to Acquire InterMune (ITMN) - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 25, 3:43PM CDT
Roche is looking to buy InterMune, sending shares of ITMN up over 35 percent on the day.

Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 25, 1:27PM CDT
Achillion Pharmaceuticals (ACHN) surged to a 52-week high of $11.15 in afternoon trading Monday after UBS tabbed the company as a possible takeover target.

Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.

The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).

Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.

New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo
PR Newswire - Wed Aug 20, 7:40AM CDT
Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.

ACHILLION PHARMA
at Investor's Business Daily - Tue Aug 19, 5:47PM CDT
ACHILLION PHARMA (ACHN) got a patent OK for ACH-3102, its hepatitis C treatment. Shares rose 2.8% after closing up 3.5%.

Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
at The Street - Tue Aug 19, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) rose in after-hours trading Tuesday after the company received a patent for its hepatitis C drug ACH-3102.

Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
GlobeNewswire - Tue Aug 19, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.

Can The Uptrend Continue for Achillion (ACHN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 6:57AM CDT
Can The Uptrend Continue for Achillion (ACHN)?

Achillion Pharmaceuticals
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
Achillion Pharmaceuticals (ACHN) was upgraded to buy from hold by Deutsche Bank, and its price target was raised to 17 from 6 on good news about its new hepatitis drug. Shares rose 3.1% to 9.5.

Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.

Should Achillion Pharma (ACHN) Be In Your Portfolio Now? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 18, 2:20PM CDT
ACHN is soaring today, but have investors already missed all the big gains?

Achillion Pharmaceuticals Up On Buyout Rumors
at Investor's Business Daily - Mon Aug 18, 12:52PM CDT
Achillion Pharmaceuticals (ACHN) stock touched an 18-month high for the second straight trading day on Monday, after Deutsche Bank upgraded the biotech startup and boosted price target on positive news about its new hepatitis drug. Achillion stock...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Activewear Faces Securities Fraud Lawsuit: Key Actions

Investors Reeling from Gildan's Stock Plunge Here we go again, folks. Gildan Activewear is making headlines, and not for reasons any stockholder wants to see. The company's embroiled in a securities fraud class action lawsuit, and if you're holding onto any NYSE:GIL shares, it's time to pay attention. This isn't some minor hiccup, either; there's heavy accusations on the...

Siemens Set to Acquire Lauterbach in Strategic Move

Siemens Seizing New Opportunities with Lauterbach Acquisition Bam! Siemens is on the move, folks, snapping up Lauterbach to bolster its semiconductor design arsenal. Now, if you’ve got your eyes glued to innovation in chip design, like yours truly, then strap in because this merger is more than just a footnote on some dusty tech page. It's a game-changer when it comes...

JD Technologies and GBG Marketing Join Forces

New Collaboration in Industrial Marketing Now here’s a twist in the industrial marketing game: JD Technologies Global (JDTG) and GBG Marketing have decided to buddy up. On this wild ride of market competition, these two are tightening their grip with a strategic partnership announced on a not-so-chill November day in Palm Coast, Florida. JDTG is sticking to its guns on...

Pyxus Starts Exchange Offer for 8.50% Notes, 2027

Pyxus Restructures Via Exchange Offer Pites, it's time for Pyxus International to show its hand. The global agricultural player has rolled up its sleeves, kicking off an exchange offer for its 8.50% notes maturing in 2027. With $148.3 million hanging in the balance, this move is their shot at managing debt and keeping things steady—like a farmer making sure the...

Bakersfield Sees Spike in Crashes Post Time Change

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

Houston's Health Museum Introduces 'Sensing Sound' Exhibit

Sound Takes Center Stage in Houston There's a new kind of hush in Houston and it ain't just the Texas sun setting low. Come November 21, The Health Museum throws its doors wide open with an exhibition that'll have visitors hearing sound like they've never imagined before. Now, I don't want to sound like a broken record, but this type of exhibition—the Sensing...

Maternal Role in Type 1 Diabetes: A Non-Genetic Angle

Unveiling the Maternal Puzzle in Type 1 Diabetes So here's a stumper: how come kids of moms with type 1 diabetes dodge the disease more than kids of dads with it? Simple genes don't account for it, says a study from University of Colorado Anschutz. With nearly 7,000 kids in this research, you'd think they'd find a genetic smoking gun. Nope. It's pointing to something else...

Durability Over Comfort: Vibram's Global Footwear Shift

Durability Takes Center Stage in Footwear Choices Out with the fleeting, in with the durable! Vibram, that powerhouse in performance soles known for its little yellow octagon logo, is grabbing durability by the laces and pushing it to the forefront of the footwear game. With a freshly minted global survey shaking things up, turns out almost 8 in 10 of us aren't just...

AptarGroup Faces Investigation: Shareholder Stakes High

AptarGroup Directors Under Investigation Every seasoned investor knows the market isn’t just sunshine and rainbows. Lately, the storm clouds have gathered over AptarGroup, Inc. (NYSE: ATR). Out of nowhere comes Purcell & Lefkowitz LLP, announcing a shareholder investigation that sends shivers down the spines of those who've put their money on this packaging...

PMET's Lithium-Tantalum Study Ups Stakes in Québec Project

Elevated Ambitions in Québec: PMET's Lithium-Tantalum Leap PMET Resources just handed us an intriguing update on their Shaakichiuwaanaan project up in Québec. They're reshaping the roadmap to crank out both lithium and tantalum more efficiently than a bear on a honeycomb. The revised feasibility study has put to paper numbers that have optimists—and skeptics...